Rxo (RXO) Net Income towards Common Stockholders (2021 - 2025)
Historic Net Income towards Common Stockholders for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to -$46.0 million.
- Rxo's Net Income towards Common Stockholders fell 8400.0% to -$46.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$100.0 million, marking a year-over-year increase of 6551.72%. This contributed to the annual value of -$100.0 million for FY2025, which is 6551.72% up from last year.
- Rxo's Net Income towards Common Stockholders amounted to -$46.0 million in Q4 2025, which was down 8400.0% from -$14.0 million recorded in Q3 2025.
- In the past 5 years, Rxo's Net Income towards Common Stockholders registered a high of $44.0 million during Q2 2022, and its lowest value of -$243.0 million during Q3 2024.
- For the 5-year period, Rxo's Net Income towards Common Stockholders averaged around -$12.9 million, with its median value being -$4.0 million (2022).
- Per our database at Business Quant, Rxo's Net Income towards Common Stockholders soared by 15000.0% in 2023 and then crashed by 2420000.0% in 2024.
- Rxo's Net Income towards Common Stockholders (Quarter) stood at $42.0 million in 2021, then crashed by 109.52% to -$4.0 million in 2022, then skyrocketed by 150.0% to $2.0 million in 2023, then tumbled by 1350.0% to -$25.0 million in 2024, then crashed by 84.0% to -$46.0 million in 2025.
- Its last three reported values are -$46.0 million in Q4 2025, -$14.0 million for Q3 2025, and -$9.0 million during Q2 2025.